Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00118404 · ClinicalTrials.gov registry record · Phase 3

Cognitive Therapy for Recurrent Depression

A Phase 3 study of Depression, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
Phase 3
Development phase
523
Enrollment target
2
Study locations

NCT00118404 is a Phase 3 study of Depression that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 523 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (33% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00118404, a Phase 3 study of Depression, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
523 participants
Enrollment target
2
Study locations

Study Summary

This study determined the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.

Conditions Studied

Interventions

  • BEHAVIORAL Continuation phase cognitive therapy
  • DRUG Continuation phase fluoxetine
  • OTHER Continuation phase pill placebo
  • BEHAVIORAL Acute phase cognitive therapy

Study Locations (2)

Pennsylvania

  • University of Pittsburgh Medical Center Western Psychiatric Institute and Clinic - Pittsburgh

Texas

  • University of Texas Southwestern Medical Center at Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 523 participants
Start Date 2000-03
Est. Completion 2008-07
Phase Phase 3

What the Registry Record Tells You About NCT00118404

The ClinicalTrials.gov registry entry for NCT00118404 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 785-participant average among 679 other Depression trials with a reported enrollment target (33% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Continuation phase cognitive therapy is the first listed.

NCT00118404 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT00118404 about?

NCT00118404 is a clinical study titled "Cognitive Therapy for Recurrent Depression". This study determined the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.

What is the current status of trial NCT00118404?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2000-03. Estimated completion is 2008-07.

What conditions does trial NCT00118404 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00118404?

The interventions under investigation include: Continuation phase cognitive therapy (BEHAVIORAL), Continuation phase fluoxetine (DRUG), Continuation phase pill placebo (OTHER), Acute phase cognitive therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00118404?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00118404 being conducted?

This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.